Form 8-K - Current report:
SEC Accession No. 0001104659-25-114660
Filing Date
2025-11-20
Accepted
2025-11-20 17:07:45
Documents
14
Period of Report
2025-11-19
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2531112d1_8k.htm   iXBRL 8-K 30706
2 EXHIBIT 99.1 tm2531112d1_ex99-1.htm EX-99.1 11948
6 GRAPHIC tm2531112d1_ex99-1img001.jpg GRAPHIC 31308
  Complete submission text file 0001104659-25-114660.txt   256207

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ewtx-20251119.xsd EX-101.SCH 3020
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ewtx-20251119_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ewtx-20251119_pre.xml EX-101.PRE 22362
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2531112d1_8k_htm.xml XML 3567
Mailing Address 1715 38TH ST BOULDER CO 80301
Business Address 1715 38TH ST BOULDER CO 80301 720-262-7002
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40236 | Film No.: 251503862
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)